CG
TAK icon

Caprock Group’s Takeda Pharmaceutical TAK Stock Holding History

Caprock Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$666K Sell
40,725
-2,416
-6% -$40K 0.01% 760
2026
Q1 		$799K Buy
43,141
+6,869
+19% +$121K 0.02% 606
2025
Q4 		$565K Sell
36,272
-17,189
-32% -$246K 0.01% 776
2025
Q3 		$801K Buy
+53,461
New +$794K 0.02% 639
2025
Q1 		$422K Buy
28,398
+2,485
+10% +$34.8K 0.01% 783
2024
Q4 		$343K Sell
25,913
-8,391
-24% -$115K 0.01% 752
2024
Q3 		$488K Buy
34,304
+2,454
+8% +$34.8K 0.02% 574
2024
Q2 		$423K Buy
31,850
+2,830
+10% +$37.5K 0.02% 586
2024
Q1 		$403K Sell
29,020
-3,887
-12% -$56.5K 0.02% 477
2023
Q4 		$470K Sell
32,907
-34,369
-51% -$488K 0.03% 404
2023
Q3 		$1.04M Buy
67,276
+9,906
+17% +$153K 0.08% 201
2023
Q2 		$915K Buy
57,370
+13,620
+31% +$223K 0.07% 231
2023
Q1 		$721K Buy
43,750
+9,609
+28% +$153K 0.06% 266
2022
Q4 		$533K Buy
+34,141
New +$477K 0.05% 272
2022
Q2 		– Sell
-18,453
Closed -$264K – 627
2022
Q1 		$264K Buy
18,453
+3,216
+21% +$47.2K 0.02% 471
2021
Q4 		$208K Buy
15,237
+3,397
+29% +$47.7K 0.02% 533
2021
Q3 		$194K Buy
+11,840
New +$199K 0.02% 505
2021
Q2 		– Sell
-16,656
Closed -$304K – 560
2021
Q1 		$304K Buy
+16,656
New +$300K 0.03% 334
2020
Q4 		– Sell
-10,887
Closed -$194K – 493
2020
Q3 		$194K Buy
10,887
+469
+5% +$8.54K 0.03% 371
2020
Q2 		$190K Buy
+10,418
New +$187K 0.03% 375

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Caprock Group's TAK Position: Q2 2026 in Review

Caprock Group reduced its Takeda Pharmaceutical (TAK) stake by 5.6% in Q2 2026, selling an estimated $40K and leaving 40,725 shares worth $666K. The position accounts for 0.01% of the portfolio, ranked #760.

Caprock Group first reported a position in TAK in Q2 2020 and has held it in 20 quarters since. The position peaked at $1.04M in Q3 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Caprock Group held 40,725 shares of Takeda Pharmaceutical worth $666K as of Q2 2026.
  • Caprock Group sold 2,416 Takeda Pharmaceutical shares in Q2 2026, an estimated $40K.
  • Takeda Pharmaceutical made up 0.01% of Caprock Group's portfolio in Q2 2026, its #760 holding.
  • Caprock Group first reported a position in Takeda Pharmaceutical in Q2 2020 and has held it in 20 quarters since.
  • Caprock Group's Takeda Pharmaceutical position peaked at $1.04M in Q3 2023.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.